Shareholders of Wilson Therapeutics AB, which is developing treatments for rare diseases, have elected Birgitte Volck and Björn Odlander to the company’s board of directors. Dr Volck is currently head of rare disease research and development at GlaxoSmithKline Plc. Prior to this she was chief medical officer and head of development at Swedish Orphan Biovitrum AB. She holds a PhD and a medical degree from Copenhagen University in Denmark.
Dr Odlander is managing partner and co-founder of the venture capital firm HealthCap. He holds a PhD and medical degree from the Karolinska Institute in Stockholm.
Wilson Therapeutics announced the appointments on 22 May 2017
Copyright 2017 Evernow Publishing Ltd